Methods of treating cancer with anti-b7h3 antibody-drug conjugates
CN122206464APending Publication Date: 2026-06-12MEDILINK THERAPEUTICS (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- MEDILINK THERAPEUTICS (SUZHOU) CO LTD
- Filing Date
- 2024-11-13
- Publication Date
- 2026-06-12
AI Technical Summary
Technical Problem
In the treatment of cancer, existing antibody-drug conjugates (ADCs) have low targeting effects, insufficient response rate, and dosage-dependent toxicity, affecting the clinical dosage and therapeutic effect.
Method used
Anti-B7H3 antibody-drug conjugates are used in combination with anti-PD-L1 antibodies or chemotherapeutic drugs for cancer treatment. This method enhances anti-tumor effects and reduces drug toxicity by targeting B7H3 antigen and regulating immune checkpoints.
Benefits of technology
It improves the anti-tumor effect of cancer treatment, enhances the durability of treatment response, and reduces dose-dependent toxicity, improving the safety and effectiveness of clinical administration.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000029_0000
Abstract
A method or use related to administering an anti-B7H3 antibody-drug conjugate in combination with other therapeutic agents selected from an anti-PD-L1 antibody or an antigen-binding fragment thereof or / and a chemotherapeutic drug for treating cancer, and a use of a pharmaceutical composition and a pharmaceutical kit of the combination for treating cancer.
Need to check novelty before this filing date? Find Prior Art